For decades, ulcers got pinned on stress and spicy food, like jalapenos were tiny criminals with motive and opportunity, until Helicobacter pylori strolled into the station holding the smoking microscope slide. Cancer biology has its own suspiciously tidy assumptions, and this week’s suspect is a family of enzymes with a misleadingly kitchen-adjacent name: salt-inducible kinases, or SIKs.
No, this does not mean ovarian cancer immunotherapy hinges on whether your fries need less seasoning. Put down the shaker. We are talking about molecular switches inside cells, not a sodium-based plot twist.
The paper in question, published in Nature Immunology, argues that SIKs may help explain why high-grade serous ovarian cancer so often gives immunotherapy the cold shoulder. The tumor, as usual, was found near the scene acting innocent. The T cells had the thousand-yard stare. The evidence bag contained malignant ascites, that fluid buildup common in advanced ovarian cancer and notorious for turning the abdomen into a very bad neighborhood for immune cells.
The Scene: A Tumor With Security Cameras Off
High-grade serous ovarian carcinoma is the most common and deadliest major subtype of ovarian cancer. It often spreads through the abdomen, can produce ascites, and has a long-standing talent for resisting immune checkpoint inhibitors, the drugs that work beautifully in some cancers by releasing the immune system’s brakes.
That failure has always been odd, because ovarian tumors can contain T cells, and T cells are supposed to be the body’s tiny armed detectives. But in ovarian cancer, many of them show up, look around, and then seem to file paperwork instead of making arrests.
Recent reviews have described ovarian cancer immunotherapy as promising but frustrating, with checkpoint inhibitor trials producing modest responses and the tumor microenvironment repeatedly showing up as the shady accomplice [1]. The microenvironment is not just “stuff around the tumor.” It is a whole local ecosystem of immune cells, cancer cells, blood vessels, fibroblasts, chemical signals, and molecular bad vibes.
The Clue: Ascites Makes T Cells Weird
Dong, Ray, Rotter and colleagues started with a practical question: what in the ovarian cancer environment shuts T cells down, and can an existing drug wake them back up?
They used an all-human drug repurposing screen. Translation: they exposed human T cells to patient-derived ovarian cancer ascites, watched those T cells lose some of their fighting spirit, then tested compounds to see what restored immune activity. In this lineup, SIK inhibitors looked suspiciously useful.
The researchers found that T cells exposed to patient ascites expressed high levels of SIKs and LKB1, an upstream kinase. When they inhibited SIK activity, the T cells started acting less like exhausted witnesses and more like trained investigators. They produced more interferon-gamma, showed stronger cytotoxic features, and generally looked better equipped to bother tumor cells [2].
That is the first reveal. The second is better: this was not just a petri-dish parlor trick.
The Suspects: SIK2 and SIK3
In mouse models of immunotherapy-resistant high-grade serous ovarian cancer, blocking SIKs improved antitumor immunity and survival. Genetic experiments pointed especially to SIK2 and SIK3 inside T cells as key drivers of the immune suppression. When the researchers removed or inhibited those signals, T cells became more active in the tumor environment.
The paper also connects SIK signaling to downstream molecular players, including TXNIP induction and LYST suppression. That sentence sounds like someone dropped a Scrabble bag into a centrifuge, so here is the plain-English version: SIK activity appears to push T cells into a less useful state through specific internal wiring. Cut that wire, and the T cells regain some bite.
The investigators also saw broader neighborhood changes. Multi-omics analyses suggested SIK inhibition reduced disease progression, increased T cell infiltration, boosted cytotoxicity, and shifted the tumor niche away from immune suppression and toward immune stimulation [2]. In noir terms: the fog lifted, the streetlights came on, and suddenly the security team remembered it had badges.
Why This Matters
Ovarian cancer has been a hard case for immunotherapy. Scientists have mapped immune evasion across ovarian tumors and found that location, tumor cell state, genetics, and spatial organization all matter [3,4]. Some tumors exclude T cells. Some invite the wrong immune cells. Some host T cells that are present but exhausted, like they have been stuck in a DMV line since 2017.
SIK inhibition is interesting because it may not simply yell “attack!” at the immune system. It may reprogram T cells so they can function inside a hostile ovarian cancer environment. Even more intriguing, combining SIK inhibition with PD-1 blockade extended survival further in the mouse models [2]. That hints at a possible strategy: do not just release the brakes, fix the engine too.
The Caution Tape
This is still early. The strongest therapeutic data come from preclinical models, not a definitive human trial. Mouse tumors have helped solve many mysteries, but they have also occasionally testified with confidence and then failed cross-examination in clinic. The next questions are obvious: Which patients would benefit? Can SIK inhibitors be dosed safely? Will the immune boost hold up in people with advanced ovarian cancer? What side effects show up when you tinker with kinases that also do normal biological jobs?
Still, the case is worth following. If these findings reproduce and expand, SIK inhibitors could become a new way to make ovarian tumors more vulnerable to immunotherapy, especially in patients whose cancers currently treat checkpoint blockade like a polite suggestion.
The tumor has not confessed. But the detectives found a fresh set of fingerprints.
References
-
Ghisoni E, Morotti M, Sarivalasis A, et al. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach. Nature Reviews Clinical Oncology. 2024. https://doi.org/10.1038/s41571-024-00937-4
-
Dong H, Ray A, Rotter LK, et al. Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer. Nature Immunology. 2026. https://doi.org/10.1038/s41590-026-02512-8
-
Yeh CY, Aguirre K, Laveroni O, et al. Mapping spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer. Nature Immunology. 2024;25:1943-1958. https://doi.org/10.1038/s41590-024-01943-5
-
Vázquez-García I, et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature. 2022;612:778-786. https://doi.org/10.1038/s41586-022-05496-1
-
Zhang H, Liu Y, et al. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis. Cell Reports Medicine. 2022. https://doi.org/10.1016/j.xcrm.2022.100856
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.